MED29

Across TCGA pan-cancer cohorts, MED29 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MED29 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED29 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED29 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where MED29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.858	0.517	.004	27	view →
PDAC	OS	Quartile	II,III,IV	0.401	0.703	.011	4	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MED29–LSCC (DFS)

Open the LSCC breakdown →